Home » Stocks » Epizyme

Epizyme, Inc. (EPZM)

Stock Price: $12.54 USD -0.31 (-2.38%)
Updated Aug 7, 2020 11:00 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 1.27B
Revenue (ttm) 13.83M
Net Income (ttm) -201.88M
Shares Out 101.48M
EPS (ttm) -2.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $12.54
Previous Close $12.84
Change ($) -0.31
Change (%) -2.38%
Day's Open 12.78
Day's Range 12.51 - 12.80
Day's Volume 169,586
52-Week Range 9.74 - 27.82

More Stats

Market Cap 1.27B
Enterprise Value 1.04B
Earnings Date (est) Oct 28, 2020
Ex-Dividend Date n/a
Shares Outstanding 101.48M
Float 83.10M
EPS (basic) -2.09
EPS (diluted) -2.00
FCF / Share -2.33
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 11.04M
Short Ratio 6.08
Short % of Float 14.41%
Beta 2.00
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 91.97
PB Ratio 4.65
Revenue 13.83M
Operating Income -204.36M
Net Income -201.88M
Free Cash Flow -235.14M
Net Cash 232.03M
Net Cash / Share 2.29
Gross Margin -786.92%
Operating Margin -1,477.56%
Profit Margin -1,459.70%
FCF Margin -1,700.12%
ROA -31.98%
ROE -65.22%
ROIC -71.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (8)

Buy 7
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$28.38*
(126.41% upside)
Low
16.0
Current: $12.54
High
36.0
Target: 28.38
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014201320122011
Revenue23.8021.7010.008.012.5641.4168.4845.226.94
Revenue Growth9.68%117%24.89%212.77%-93.82%-39.53%51.44%551.24%-
Gross Profit23.8021.7010.008.012.5641.4168.4845.226.94
Operating Income-177-128-137-112-133-55.05-3.13-0.77-20.97
Net Income-170-124-134-110-132-55.01-3.48-0.70-20.96
Shares Outstanding89.8971.8661.4757.1339.8433.0317.051.651.43
Earnings Per Share-1.93-1.72-2.18-1.93-3.32-1.67-0.22-0.72-14.65
Operating Cash Flow-147-122-120-96.37-72.93-35.36-53.7344.1510.00
Capital Expenditures-0.59-0.30-0.98-0.62-0.18-2.22-0.63-1.48-0.92
Free Cash Flow-148-122-121-97.00-73.11-37.58-54.3642.679.08
Cash & Equivalents38124027624220819012497.9833.34
Total Debt45.47-0.110.731.29----
Net Cash / Debt33624027624120719012497.9833.34
Assets42527628925221819916310437.36
Liabilities93.4542.4953.9950.7448.3738.9258.6815588.00
Book Value331233235202170160104-51.13-50.64
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Epizyme, Inc.
Country United States
Employees 203
CEO Robert B. Bazemore

Stock Information

Ticker Symbol EPZM
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: EPZM
IPO Date May 31, 2013

Description

Epizyme, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors. It also develops tazemetostat in combination with R-CHOP that is in the Phase Ib/II clinical trials in elderly patients with DLBCL; and tazemetostat in combination with PD-L1 inhibitor, which is in the Phase Ib/II clinical trials for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer. In addition, the company is developing EZM8266, a G9a inhibitor that is in the Phase 1 study for the treatment of sickle cell disease; pinometostat, which is in the preclinical studies stage for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; PRMT5 inhibitor that is in Phase II clinical trial for patients with solid tumors and NHL; and PRMT1 inhibitor, which is in the Phase 1 clinical trial. Epizyme, Inc. has collaboration agreements with Celgene Corporation; Genentech Inc.; Glaxo Group Limited; Boehringer Ingelheim International GmbH; Roche Molecular Systems, Inc.; Lymphoma Study Association; and Eisai Co. Ltd. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.